RxDoctor Payments Data

Tracie Watson, DO

Hematology & Oncology · Walnut Creek, CANPI 1275875965

Payments from drug & device makers

$8,153in general payments, 2019–2025

Across 327 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$612
  • Pharmacyclics LLC, An Abbvie Company$534
  • E.r. Squibb & Sons, L.L.C.$475
  • Gilead$418
  • Johnson & Johnson$410
  • AstraZeneca$338
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,41791%
  • Education$7359%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer29$612
Pharmacyclics LLC, An Abbvie Company13$534
E.r. Squibb & Sons, L.L.C.22$475
Gilead(2 entities)22$418
Johnson & Johnson16$410
AstraZeneca(2 entities)13$338
Sanofi11$337
Seagen Inc.9$330
GSK13$319
Novartis12$309
Daiichi Sankyo Inc.14$305
Astellas Pharma US Inc15$299
Bristol Myers Squibb14$283
Merck6$265
Takeda Pharmaceuticals U.S.A., Inc.8$228
AbbVie9$212
Amgen6$210
Lilly USA, LLC7$161
Tersera Therapeutics LLC6$144
Myovant Sciences Inc.5$126
Incyte Corporation4$117
Bayer5$109
Puma Biotechnology, Inc.4$93
EMD Serono, Inc.3$91
Ipsen Biopharmaceuticals, Inc4$88
Servier Pharmaceuticals LLC4$74
Genentech USA, Inc.3$74
Octapharma USA, Inc.2$67
Spectrum Pharmaceuticals Inc.3$63
Array Biopharma Inc3$61
Regeneron Healthcare Solutions, Inc.2$61
Sumitomo Pharma America, Inc.2$59
Sobi, Inc2$58
Kyowa Kirin, Inc.2$56
Beigene USA, Inc.3$51
Taiho Oncology, Inc.2$50
Pharmacosmos Therapeutics Inc.2$48
Eisai Inc.2$47
Blueprint Medicines Corporation1$33
Dendreon Pharmaceuticals LLC1$31
Immunocore Limited1$31
Foundation Medicine, Inc.1$29
Adaptive Biotechnologies Corporation1$28
Genmab U.S., Inc.1$27
Stemline Therapeutics Inc.1$26
Rigel Pharmaceuticals, Inc.1$26
Invivyd Inc1$25
Acrotech Biopharma Inc.1$25
Springworks Therapeutics, Inc.1$25
Exelixis Inc.1$24
Beone Medicines USA, Inc.1$23
Epizyme, Inc.1$23
Boehringer Ingelheim1$22
Apellis Pharmaceuticals, Inc.1$22
Deciphera Pharmaceuticals Inc.1$22
Galvanize Therapeutics, Inc1$21
AMAG Pharmaceuticals, Inc.1$20
Heron Therapeutics, Inc.1$19
Accord Healthcare, Inc.1$19
ADC Therapeutics America, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,153 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$1,865,566
Medicare patients
235
Services billed
97,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib24$349,960
Darzalex FasproDaratumumab-Hyaluronidase-Fihj35$340,972
TagrissoOsimertinib Mesylate12$203,938
CalquenceAcalabrutinib Maleate13$190,190
PromactaEltrombopag Olamine13$160,486
Abiraterone Acetate41$114,700
XgevaDenosumab26$84,454
NeulastaPegfilgrastim12$75,722
Imatinib Mesylate12$31,903
EliquisApixaban17$14,480
Letrozole19$520
Mirtazapine11$182
Prednisone30$144
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$338$394,12825 claims
Beigene USA, Inc.Brukinsa$51$349,96024 claims
NovartisPromacta$309$160,48613 claims
AmgenXgeva, Neulasta$210$160,17738 claims
PfizerEliquis$612$14,48017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →